Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy.

Lerman C, Jepson C, Wileyto EP, Patterson F, Schnoll R, Mroziewicz M, Benowitz N, Tyndale RF.

Clin Pharmacol Ther. 2010 May;87(5):553-7. doi: 10.1038/clpt.2010.3. Epub 2010 Mar 24.

2.

Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes.

Ray R, Tyndale RF, Lerman C.

J Neurogenet. 2009;23(3):252-61. doi: 10.1080/01677060802572887. Epub 2009 Jan 23. Review.

3.

Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence.

Malaiyandi V, Sellers EM, Tyndale RF.

Clin Pharmacol Ther. 2005 Mar;77(3):145-58. Review.

PMID:
15735609
4.

Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior.

Tyndale RF, Sellers EM.

Ther Drug Monit. 2002 Feb;24(1):163-71. Review.

PMID:
11805739
5.

Genetic and environmental influences on therapeutic and toxicity outcomes: studies with CYP2A6.

Satarug S, Tassaneeyakul W, Na-Bangchang K, Cashman JR, Moore MR.

Curr Clin Pharmacol. 2006 Sep;1(3):291-309. Review.

PMID:
18666753
6.

CYP2A6 genetic variation and potential consequences.

Xu C, Goodz S, Sellers EM, Tyndale RF.

Adv Drug Deliv Rev. 2002 Nov 18;54(10):1245-56. Review.

PMID:
12406643
7.

Transdermal nicotine patches with low-intensity support to aid smoking cessation in outpatients in a general hospital. A placebo-controlled trial.

Foulds J, Stapleton J, Hayward M, Russell MA, Feyerabend C, Fleming T, Costello J.

Arch Fam Med. 1993 Apr;2(4):417-23. Review.

PMID:
8130921
8.

Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.

Benowitz NL.

Clin Pharmacol Ther. 2008 Apr;83(4):531-41. doi: 10.1038/clpt.2008.3. Epub 2008 Feb 27. Review.

PMID:
18305452
9.

Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour.

Tricker AR.

Toxicology. 2003 Feb 1;183(1-3):151-73. Review.

PMID:
12504349
10.

Overview of the pharmacogenomics of cigarette smoking.

Ho MK, Tyndale RF.

Pharmacogenomics J. 2007 Apr;7(2):81-98. Epub 2007 Jan 16. Review.

PMID:
17224913
11.

Smoking behavior and related cancers: the role of CYP2A6 polymorphisms.

Nakajima M.

Curr Opin Mol Ther. 2007 Dec;9(6):538-44. Review.

PMID:
18041664
12.

Transdermal nicotine replacement and smoking cessation.

McKenna JP, Cox JL.

Am Fam Physician. 1992 Jun;45(6):2595-602. Review.

PMID:
1595510
13.

Tobacco addiction and pharmacogenetics of nicotine metabolism.

Swan GE, Lessov-Schlaggar CN.

J Neurogenet. 2009;23(3):262-71. doi: 10.1080/01677060802572903. Epub 2009 Jan 19. Review.

PMID:
19152209
14.

New medications for nicotine dependence treatment.

Hurt RD.

Nicotine Tob Res. 1999;1 Suppl 2:S175-9; discussion S207-10. Review.

PMID:
11768177
15.

Molecular genetics of nicotine metabolism.

Mwenifumbo JC, Tyndale RF.

Handb Exp Pharmacol. 2009;(192):235-59. doi: 10.1007/978-3-540-69248-5_9. Review.

PMID:
19184652
16.

Nicotine replacement therapy for smoking cessation.

Silagy C, Mant D, Fowler G, Lancaster T.

Cochrane Database Syst Rev. 2000;(3):CD000146. Review. Update in: Cochrane Database Syst Rev. 2001;(3):CD000146.

PMID:
10908462
17.

The pros and cons of transdermal nicotine therapy.

Gourlay S.

Med J Aust. 1994 Feb 7;160(3):152-9. Review.

PMID:
8295585
18.

Nicotine replacement therapy for smoking cessation.

Silagy C, Lancaster T, Stead L, Mant D, Fowler G.

Cochrane Database Syst Rev. 2001;(3):CD000146. Review. Update in: Cochrane Database Syst Rev. 2002;(4):CD000146.

PMID:
11686953
19.

Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6.

Nakajima M, Kuroiwa Y, Yokoi T.

Drug Metab Rev. 2002 Nov;34(4):865-77. Review.

PMID:
12487152
20.

PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6.

McDonagh EM, Wassenaar C, David SP, Tyndale RF, Altman RB, Whirl-Carrillo M, Klein TE.

Pharmacogenet Genomics. 2012 Sep;22(9):695-708. doi: 10.1097/FPC.0b013e3283540217. Review. No abstract available.

Supplemental Content

Support Center